Literature DB >> 1797083

Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities.

R Berger1, M Le Coniat, J Derré, D Vecchione, P Jonveaux.   

Abstract

A series of 105 patients with acute promyelocytic leukemia (APL) has been cytogenetically investigated at the Department of Hematology of the Saint-Louis Hospital (Paris) between 1977 and 1990. Sixty-two patients were examined at diagnosis, 32 in relapse, and 11 both at diagnosis and in relapse. The typical t(15;17)(q22;q12) or variants of this translocation were observed in all but four patients. The t(15;17) was the only change in 47 cases at diagnosis and in 21 examined in relapse. The most frequent secondary change was trisomy 8 (17% at diagnosis). More or less complex chromosomal abnormalities in addition to t(15;17) were present in six patients at diagnosis, and in 17 patients in relapse. Rearrangements of 2q35-q37 and del(11p) were observed only in relapse and may thus be nonrandom secondary changes. Cytogenetic studies performed on 19 patients treated with all-trans retinoic acid did not indicate that this treatment induces chromosomal abnormalities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797083     DOI: 10.1002/gcc.2870030503

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  18 in total

1.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

2.  An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles.

Authors:  J G Thomas; J M Olson; S J Tapscott; L P Zhao
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

3.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

Authors:  Robert E Gallagher; Barry K Moser; Janis Racevskis; Xavier Poiré; Clara D Bloomfield; Andrew J Carroll; Rhett P Ketterling; Diane Roulston; Esther Schachter-Tokarz; Da-Cheng Zhou; I-Ming L Chen; Richard Harvey; Greg Koval; Dorie A Sher; James H Feusner; Martin S Tallman; Richard A Larson; Bayard L Powell; Frederick R Appelbaum; Elisabeth Paietta; Cheryl L Willman; Wendy Stock
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

4.  Effect of additional chromosomal abnormalities in acute promyelocytic leukemia treated with all-trans-retinoic acid: a report of 17 patients.

Authors:  Y Okoshi; H Akiyama; N Kono; T Matsumura; D Mizuchi; S Mori; K Ohashi; H Sakamaki
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

5.  Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence.

Authors:  M Pantic; A Novak; D Marisavljevic; V Djordjevic; I Elezovic; A Vidovic; M Colovic
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

6.  Clinico-biological features of 30 patients with acute promyelocytic leukemia and response to combination induction chemotherapy with all-trans retinoic acid and anthracycline.

Authors:  L C Lim; M Vellupillai; A A Ghafar
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

Review 7.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

8.  Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures.

Authors:  Matthew J Walter; John S Park; Steven K M Lau; Xia Li; Andrew A Lane; Rakesh Nagarajan; William D Shannon; Timothy J Ley
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  PML, a growth suppressor disrupted in acute promyelocytic leukemia.

Authors:  Z M Mu; K V Chin; J H Liu; G Lozano; K S Chang
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

10.  Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.

Authors:  Blaine W Robinson; Nai-Kong V Cheung; Christos P Kolaris; Suresh C Jhanwar; John K Choi; Neil Osheroff; Carolyn A Felix
Journal:  Blood       Date:  2008-01-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.